Tamaka Shwasa and Allergic Asthma: A Critical Narrative Review of Classical Ayurvedic Concepts and Contemporary Biomedical Evidence
Puneeth Raj R M*1, Shivani Koul2, Vikas Mishra3, Mohar Pal Meena4,
Reetesh Ramnani5, Anupam Srivastava6
1PG Scholar, Department of Rasa Shastra Evum Bhaishajya Kalpana,
National Institute of Ayurveda Deemed University, Amer Rd, Jaipur, Rajasthan, India.
2PhD Scholar, Department of Rasa Shastra Evum Bhaishajya Kalpana,
National Institute of Ayurveda Deemed University, Amer Rd, Jaipur, Rajasthan, India.
3PG Scholar, Department of Rasa Shastra Evum Bhaishajya Kalpana,
National Institute of Ayurveda Deemed University, Amer Rd, Jaipur, Rajasthan, India.
4 Professor, Department of Rasa Shastra Evum Bhaishajya Kalpana,
National Institute of Ayurveda Deemed University, Amer Rd, Jaipur, Rajasthan, India.
5Assistant Professor, Department of Rasa Shastra Evum Bhaishajya Kalpana,
National Institute of Ayurveda Deemed University, Amer Rd, Jaipur, Rajasthan, India.
6Head of Department, Department of Rasa Shastra Evum Bhaishajya Kalpana,
National Institute of Ayurveda Deemed University, Amer Rd, Jaipur, Rajasthan, India.
*Corresponding Author E-mail: puneethjayesh@gmail.com
ABSTRACT:
Background: Allergic asthma is a chronic inflammatory airway disease characterized by reversible airflow obstruction, bronchial hyper-responsiveness, and immune dysregulation involving immunoglobulin E (IgE), eosinophils, and T-helper 2 (Th2) cytokines. Despite advances in conventional therapy, disease recurrence, adverse drug effects, and incomplete symptom control remain major challenges. In Ayurveda, Tamaka Shwasa, a subtype of Shwasa Roga, closely resembles allergic asthma in its etiopathogenesis, clinical presentation, and chronic recurrent nature. Objective: To critically review the Ayurvedic concept of Tamaka Shwasa and correlate its etiopathogenesis, clinical manifestations, and management principles with the contemporary understanding of allergic asthma. Materials and Methods: A comprehensive narrative review was conducted using classical Ayurvedic texts, including the Charaka Samhita, Sushruta Samhita, and Ashtanga Hridaya, along with contemporary peer-reviewed literature on allergic asthma. Classical concepts were critically compared with modern evidence to identify conceptual and pathophysiological correlations. Results: The classical description of Tamaka Shwasa shows several clinically relevant similarities to allergic asthma, including recurrent dyspnoea, wheezing, cough, mucus-associated obstruction, nocturnal aggravation, environmental trigger sensitivity, and a chronic relapsing course. Concepts such as Kapha-induced Srotorodha and Pratiloma Gati of Prāṇa Vāyu may provide interpretative frameworks for understanding airway obstruction and disturbed respiratory function. However, terms such as Doṣa, Agni, Āma, and Srotas have no established direct biomedical equivalents, and proposed correlations with airway inflammation, mucus hypersecretion, and immune dysregulation should be regarded as hypothesis-generating rather than biologically proven. Conclusion: Tamaka Shwasa demonstrates substantial clinical and functional similarities with allergic asthma. However, Ayurvedic concepts such as Doṣa, Agni, Āma, and Srotas have no established direct biomedical equivalents. Integrative interpretation may generate useful research hypotheses, but further experimental and clinical studies are required before therapeutic conclusions or clinical recommendations can be made."
Allergic asthma is a chronic inflammatory airway disease characterized by reversible airflow obstruction, bronchial hyper-responsiveness, and recurrent episodes of wheezing, cough, chest tightness, and dyspnoea. The disease results from complex interactions between genetic susceptibility and environmental exposures, leading to persistent airway inflammation mediated by immunoglobulin E (IgE), eosinophils, mast cells, and T-helper 2 (Th2) cytokines.1
Asthma remains one of the leading chronic respiratory diseases worldwide, affecting approximately 262 million people and accounting for more than 450,000 deaths annually. Increasing urbanization, environmental pollution, occupational allergens, tobacco smoke, climate change, and altered lifestyle patterns have contributed significantly to the rising prevalence of allergic asthma, particularly in low- and middle-income countries.2
Although inhaled corticosteroids, β₂-agonists, leukotriene receptor antagonists, and biological agents have substantially improved asthma management, many patients continue to experience recurrent exacerbations, persistent airway inflammation, medication-related adverse effects, and impaired quality of life. Consequently, there is growing interest in complementary and integrative therapeutic approaches that not only alleviate symptoms but also target the underlying mechanisms responsible for disease progression.3
In Ayurveda, Tamaka Shwasa, one of the five subtypes of Shwasa Roga, closely resembles allergic asthma in its etiology, pathogenesis, clinical manifestations, chronicity, and recurrent nature. Acharya Charaka describes Tamaka Shwasa as a disorder caused predominantly by the vitiation of Kapha and Vata Dosha, resulting in obstruction (Srotorodha) of the Pranavaha Srotas and abnormal (Pratiloma) movement of Prana Vayu. These pathological events manifest clinically as Shwasa (dyspnoea), Kasa (cough), Ghurghuraka (wheezing), Uraḥ Pīḍā (chest tightness), orthopnoea, and temporary relief following expectoration of sputum.4
From a biomedical perspective, allergic asthma is characterized by chronic airway inflammation, bronchoconstriction, mucus hypersecretion, epithelial injury, and airway remodeling secondary to allergen-induced immune activation. These pathological changes show remarkable conceptual similarities with Ayurvedic principles such as Kapha-induced Srotorodha, Agnimandya, Ama formation, and derangement of Prana Vayu, providing a conceptual and hypothesis-generating framework for comparing Tamaka Shwasa with allergic asthma.5
The Ayurvedic management of Tamaka Shwasa emphasizes Nidana Parivarjana (avoidance of causative factors), Shodhana, Shamana, Pathya–Apathya, and Vatanulomana therapies to restore Dosha equilibrium, improve respiratory function, and prevent recurrence. These principles align with the modern concept of long-term disease control and personalized management of chronic airway inflammation.6
Therefore, integrating classical Ayurvedic knowledge with contemporary biomedical evidence may provide a broader understanding of allergic asthma and facilitate the development of holistic, patient-centered management strategies. The present review critically evaluates the Ayurvedic concept of Tamaka Shwasa and correlates its Nidana, Samprapti, clinical features, and therapeutic principles with the current understanding of allergic asthma to identify areas of convergence and future research opportunities.7
MATERIALS AND METHODS:
A structured narrative review was conducted to examine the classical Ayurvedic description of Tamaka Shwasa, the contemporary biomedical understanding of allergic asthma, and the available experimental and clinical evidence concerning Ayurvedic medicinal interventions relevant to allergic airway disease. Classical information was obtained from the Charaka Samhita, Sushruta Samhita, Ashtanga Hridaya, Madhava Nidana, and Bhavaprakasha, together with recognized editions, translations, and commentaries.
Electronic literature searches were conducted in PubMed/ MEDLINE, Scopus, Web of Science, and Google Scholar for publications available up to July 2026. The final search was conducted in July 2026. Search terms included “allergic asthma,” “bronchial asthma,” “airway inflammation,” “type 2 inflammation,” “eosinophilic asthma,” “Tamaka Shwasa,” “Ayurveda and asthma,” “Ayurvedic medicinal plants,” “Adhatoda vasica,” “Piper longum,” “Solanum xanthocarpum,” “Glycyrrhiza glabra,” “herbal inhalation,” and “pulmonary drug delivery.” Boolean operators AND and OR were used where appropriate.
Peer-reviewed original studies, systematic reviews, narrative reviews, authoritative clinical guidelines, classical Ayurvedic texts, pharmacological studies, toxicological investigations, and relevant clinical trials published in English were considered. Studies were selected according to their relevance to disease pathogenesis, clinical presentation, diagnosis, therapeutic intervention, pharmacological activity, pulmonary delivery, safety, or translational potential. Publications with insufficient methodological information, unverifiable bibliographic details, duplicate reporting, or no direct relevance to allergic asthma or Tamaka Shwasa were excluded.
Titles and abstracts were initially screened for relevance, followed by full-text assessment of potentially eligible publications. Reference lists of relevant articles were also examined to identify additional studies. Because the review aimed to interpret evidence derived from distinct medical knowledge systems rather than calculate a pooled treatment effect, the findings were synthesized narratively.
Ayurvedic and biomedical concepts were compared according to clinical manifestations, functional characteristics, disease course, and therapeutic principles without assuming direct biological equivalence. The manuscript was prepared with reference to the Scale for the Assessment of Narrative Review Articles (SANRA). No formal quality assessment or risk-of-bias assessment was performed because this was a narrative review.
Classical Concept of Tamaka Shwasa:
Tamaka Shwasa is one of the five varieties of Shwasa Roga described in Ayurvedic classics and is widely considered the disease entity that most closely resembles allergic asthma. The word Tamaka is derived from the Sanskrit root Tamas, meaning darkness or obscurity, reflecting the patient's perception of darkness before the eyes during severe attacks of breathlessness. Shwasa denotes the process of respiration. Thus, Tamaka Shwasa refers to a chronic respiratory disorder characterized by recurrent episodes of dyspnoea, wheezing, cough, chest tightness, and difficult expectoration.8
According to the Ayurvedic classics, Tamaka Shwasa is predominantly a Kapha–Vata Pradhana Vyadhi. The disease develops when aggravated Kapha Doṣa obstructs the Prāṇavaha Srotas, causing derangement of Prāṇa Vāyu. The resulting abnormal movement of Vāta (Pratiloma Gati) manifests as respiratory distress, wheezing (Ghurghuraka), cough (Kāsa), and repeated attacks of breathlessness. Owing to its chronic and relapsing nature, the disease is described as Yāpya, implying that complete cure may not always be achievable, although satisfactory long-term control is possible with appropriate management.9
The etiopathogenesis of Tamaka Shwasa involves prolonged exposure to dietary, environmental, and behavioural factors that disturb the equilibrium of Doṣas. Excessive intake of heavy, cold, unctuous, and incompatible foods impairs digestive fire (Agni), leading to the formation of Āma. Simultaneously, exposure to dust, smoke, cold air, excessive physical exertion, suppression of natural urges, and irregular lifestyle practices aggravates Kapha and Vāta. The accumulated Āma and aggravated Kapha obstruct the respiratory passages, while disturbed Prāṇa Vāyu produces the characteristic clinical manifestations of the disease.10
Clinically, patients experience recurrent episodes of dyspnoea that worsen during exposure to cold weather, dust, smoke, cloudy climate, and physical exertion. Relief is often obtained after expectoration of sputum and by assuming an upright sitting posture. Other associated manifestations include persistent cough, wheezing, chest tightness, disturbed sleep, anxiety, and fatigue. Classical literature further describes Santamaka Shwasa and Pratamaka Shwasa as important subtypes representing severe clinical presentations with nocturnal aggravation and association with fever, respectively.11
The principles of management emphasize the elimination of causative factors (Nidāna Parivarjana), restoration of digestive and metabolic functions, removal of Āma, correction of Doṣa imbalance, and maintenance of the patency of the Prāṇavaha Srotas. Therapeutic interventions include Śodhana procedures, Śamana medications, Rasāyana therapy, and appropriate dietary and lifestyle modifications. Several medicinal plants such as Vāsā (Adhatoda vasica), Pippalī (Piper longum), Kaṇṭakārī (Solanum xanthocarpum), and Yaṣṭimadhu (Glycyrrhiza glabra) have been traditionally recommended because of their bronchodilatory, expectorant, anti-inflammatory, and immunomodulatory properties.12
The classical description of Tamaka Shwasa demonstrates substantial clinical and functional similarities with allergic asthma, particularly regarding recurrent respiratory obstruction, episodic exacerbations, trigger sensitivity, mucus-associated breathing difficulty, nocturnal worsening, and chronicity. However, Ayurvedic concepts such as Kapha, Vāta, Āma, and Srotorodha should not be considered direct equivalents of eosinophilic inflammation, bronchial hyper-responsiveness, or immune dysregulation. These similarities should therefore be interpreted as comparative clinical observations and hypothesis-generating associations rather than proof of identical pathophysiological mechanisms.13
Modern Concept of Allergic Asthma:
Allergic asthma is the most prevalent phenotype of bronchial asthma and is characterized by chronic airway inflammation, reversible airflow limitation, bronchial hyper-responsiveness, and recurrent episodes of wheezing, dyspnoea, chest tightness, and cough. It is an immune-mediated disorder predominantly driven by immunoglobulin E (IgE)-associated hypersensitivity following sensitization to environmental allergens. Persistent airway inflammation results in variable respiratory symptoms that fluctuate over time and in intensity, often worsening at night or during early morning hours.14
The global burden of asthma remains substantial, although prevalence, incidence, mortality, and disability vary considerably according to age, geographical region, socioeconomic conditions, environmental exposure, diagnostic practices, and access to effective treatment. Recent Global Burden of Disease analyses suggest that age-standardized prevalence and incidence have declined globally over recent decades, while the absolute number of affected individuals and the burden in several populous and resource-limited regions remain considerable.15
The development of allergic asthma results from a complex interaction between genetic susceptibility and environmental exposures. Individuals with a family history of atopy are at increased risk of developing allergic sensitization. Exposure to aeroallergens such as house dust mites, pollens, fungal spores, animal dander, cockroach allergens, occupational sensitizers, and environmental pollutants initiates an exaggerated immune response. Additional risk factors, including tobacco smoke, viral respiratory infections during childhood, obesity, and reduced microbial exposure in early life, further increase disease susceptibility.16
Immunologically, allergic asthma is characterized by activation of dendritic cells following allergen exposure, leading to differentiation of naïve T lymphocytes into T-helper 2 (Th2) cells. These cells secrete interleukin (IL)-4, IL-5, and IL-13, which stimulate IgE synthesis, eosinophilic recruitment, mast-cell activation, goblet-cell hyperplasia, and mucus hypersecretion. Re-exposure to the allergen causes cross-linking of allergen-specific IgE on mast cells, resulting in the release of histamine, leukotrienes, prostaglandins, and other inflammatory mediators responsible for acute bronchoconstriction. Persistent inflammation subsequently leads to airway remodeling characterized by subepithelial fibrosis, smooth-muscle hypertrophy, angiogenesis, and irreversible structural changes in severe disease.17
Asthma is now recognized as a heterogeneous syndrome comprising multiple phenotypes and endotypes. Type 2-high asthma commonly involves eosinophilic inflammation, elevated IgE, increased fractional exhaled nitric oxide, and cytokines such as IL-4, IL-5, and IL-13. In contrast, type 2-low asthma may be characterized by neutrophilic, paucigranulocytic, obesity-associated, smoking-related, or corticosteroid-insensitive patterns. This heterogeneity is clinically important because not every patient with asthma exhibits identical inflammatory pathways or responds uniformly to the same treatment. Therefore, any proposed Ayurvedic or herbal intervention should be evaluated in clearly defined asthma phenotypes rather than in asthma as a single homogeneous disease entity.17,22
Clinically, allergic asthma presents with recurrent wheezing, shortness of breath, chest tightness, and cough that vary in frequency and severity. Symptoms are frequently precipitated by allergen exposure, exercise, respiratory tract infections, cold air, emotional stress, or environmental irritants. Many patients also exhibit associated allergic disorders such as allergic rhinitis, eczema, or conjunctivitis, supporting the systemic nature of atopic disease.18
Diagnosis is established through detailed clinical history, physical examination, and objective demonstration of variable airflow limitation using spirometry with bronchodilator reversibility testing. Additional investigations such as peak expiratory flow variability, fractional exhaled nitric oxide (FeNO), peripheral blood eosinophil count, serum total and allergen-specific IgE estimation, skin-prick testing, and allergen identification are useful for confirming allergic sensitization and phenotyping the disease. Accurate diagnosis facilitates personalized treatment and improves long-term disease control.19
Current management focuses on achieving optimal symptom control, preventing acute exacerbations, preserving lung function, and minimizing treatment-related adverse effects. Standard pharmacotherapy includes inhaled corticosteroids, long-acting β₂-agonists, leukotriene receptor antagonists, long-acting muscarinic antagonists, and biologic therapies targeting IgE, IL-5, IL-4 receptor α, and thymic stromal lymphopoietin pathways in selected patients with severe disease. Comprehensive asthma care also includes allergen avoidance, smoking cessation, patient education, vaccination, and regular follow-up to improve adherence and clinical outcomes.20
Correlation between Tamaka Shwasa and Allergic Asthma:
Tamaka Shwasa is widely accepted as the Ayurvedic disease entity that most closely resembles allergic asthma because both conditions exhibit striking similarities in etiology, pathogenesis, clinical manifestations, chronicity, and response to environmental triggers. Although the conceptual frameworks differ, both systems describe a chronic relapsing respiratory disorder characterized by episodic airway obstruction, respiratory distress, and recurrent exacerbations.21
From the Ayurvedic perspective, Tamaka Shwasa is primarily a Kapha–Vata Pradhana Vyadhi resulting from obstruction of the Prāṇavaha Srotas by aggravated Kapha Doṣa, followed by abnormal movement (Pratiloma Gati) of Prāṇa Vāyu. This sequence culminates in dyspnoea, wheezing, cough, chest tightness, and difficult expectoration. In contrast, modern medicine attributes allergic asthma to chronic airway inflammation caused by allergen-induced activation of immune cells, eosinophilic infiltration, mucus hypersecretion, bronchial smooth muscle contraction, and reversible airflow limitation. Despite differences in terminology, both systems recognize airway obstruction as the principal mechanism responsible for respiratory symptoms.22
The etiological factors described in Ayurveda closely parallel recognized environmental triggers of allergic asthma. Classical descriptions of exposure to dust (Raja), smoke (Dhūma), cold air (Śīta), excessive physical exertion, and seasonal variations correspond well with modern evidence identifying aeroallergens, air pollution, tobacco smoke, occupational irritants, respiratory infections, and climatic changes as important precipitating factors for asthma exacerbations.23
The concept of Āma, traditionally associated with impaired digestion, incomplete transformation, and pathological accumulation, has no established direct biomedical equivalent. It may be discussed cautiously as a systems-level concept involving disturbed physiological processing and accumulation of disease-promoting factors. Comparisons with chronic inflammation, oxidative stress, metabolic dysregulation, or altered immune function remain hypothetical and require experimental validation. Accordingly, Āma should not be presented as synonymous with inflammatory mediators, toxins, metabolic waste, or any single biomedical entity.24
Figure 1: conceptual correlation between the ayurvedic pathway of tamaka shwasa and the immunological pathway of allergic asthma.
Abbreviations: igE, immunoglobulin E; IL, Interleukin, Th2, T-Helper 2
Clinical manifestations of both diseases also exhibit remarkable similarity. Recurrent wheezing, breathlessness, cough, chest tightness, nocturnal worsening, and relief following expectoration described in Tamaka Shwasa closely correspond to the characteristic symptoms of allergic asthma. Furthermore, the chronic relapsing course and incomplete cure described as Yāpya in Ayurveda parallels the modern understanding that asthma is a controllable but generally lifelong inflammatory disease requiring long-term management.25
Therapeutically, both systems aim to restore normal airway function and prevent disease recurrence. Modern asthma management focuses on suppression of airway inflammation through inhaled corticosteroids, bronchodilators, leukotriene modifiers, and biological agents, whereas Ayurvedic management emphasizes Nidāna Parivarjana, Śodhana, Śamana, Rasāyana, and lifestyle regulation to restore Doṣa equilibrium and improve respiratory function. Increasing experimental evidence suggests that several Ayurvedic medicinal plants possess anti-inflammatory, antioxidant, bronchodilatory, and immunomodulatory activities that may complement conventional asthma therapy.26
The growing understanding of immunological mechanisms underlying allergic asthma, together with advances in pharmacological research on Ayurvedic medicinal plants, provides opportunities for developing evidence-based integrative treatment strategies. Future multidisciplinary research combining classical Ayurvedic principles with contemporary biomedical approaches may contribute to safer, more effective, and personalized management of chronic allergic airway diseases.27
Table 1: Critical comparison of Ayurvedic and Proposed functional/clinical comparison
|
Ayurvedic concept |
Classical interpretation |
Proposed biomedical comparison |
Strength of comparison |
|
Kapha-induced Srotorodha |
Obstruction associated with heaviness and secretions |
Secretion-associated airway obstruction |
Moderate clinical similarity |
|
Pratiloma Gati of Prāṇa Vāyu |
Abnormal movement of respiratory Vāyu |
Disturbed expiratory airflow and bronchoconstriction |
Functional analogy |
|
Ghurghuraka |
Audible respiratory sound |
Wheezing |
Strong clinical similarity |
|
Improvement after expulsion of Kapha |
Relief after expectoration |
Temporary reduction of secretion-related obstruction |
Clinical similarity |
|
Nocturnal aggravation |
Increased symptoms at night |
Nocturnal asthma variability |
Strong clinical similarity |
|
Agnimandya and Āma |
Impaired transformation and pathological accumulation |
No established direct equivalent |
Hypothesis-generating only |
|
Yāpya nature |
Long-term controllable but difficult-to-cure disorder |
Chronic disease requiring continuing control |
Broad clinical similarity |
|
Nidāna Parivarjana |
Avoidance of causative and aggravating factors |
Allergen and trigger avoidance |
Strong management similarity |
|
Śamana therapy |
Symptom-modifying and Doṣa-balancing treatment |
Pharmacological symptom control |
Broad therapeutic analogy |
Ayurvedic medicinal plants have traditionally been used in the management of Tamaka Shwasa, Kāsa, excessive expectoration, chest congestion, and recurrent respiratory discomfort. Contemporary experimental investigations suggest that selected plants possess antitussive, expectorant, anti-inflammatory, antiallergic, antioxidant, mast-cell-modulating, mucus-regulating, and immunomodulatory properties. However, the strength of evidence varies considerably among individual plants and formulations. Traditional use and pharmacological activity should not be interpreted as proof of clinical efficacy in allergic asthma.28,29,33
Adhatoda vasica Nees, traditionally known as Vāsā, contains quinazoline alkaloids, principally vasicine and vasicinone. Experimental evidence supports its antitussive activity, while ethnopharmacological and pharmacological literature describes expectorant, secretolytic, and respiratory effects associated with the plant and its constituents.28,29
Dhuley evaluated the antitussive effect of an Adhatoda vasica extract in animal models in which coughing was induced through mechanical or chemical stimulation. The findings support antitussive potential but do not establish efficacy in human allergic asthma.28 Claeson and colleagues reviewed the plant’s traditional uses, phytochemistry, pharmacological properties, and toxicological evidence, providing broader support for its respiratory relevance.29
Nevertheless, results from experimentally induced cough models, isolated tissues, and pharmacological experiments should not be considered proof of clinical effectiveness against allergic asthma. Botanical authentication, plant part, alkaloid concentration, extraction method, dose, toxicity, formulation characteristics, and route of administration must be evaluated before therapeutic translation.28,29
Several other Ayurvedic plants have been investigated for pharmacological activities potentially relevant to allergic asthma. Frequently discussed examples include Solanum xanthocarpum, Piper longum, Glycyrrhiza glabra, Ocimum tenuiflorum, Curcuma longa, Zingiber officinale, Tinospora cordifolia, Boswellia serrata, and Tylophora indica. Their reported actions include modulation of inflammatory mediators, attenuation of oxidative stress, reduction of inflammatory-cell recruitment, suppression of mucus hypersecretion, and modification of allergic airway responses. Most of these observations arise from laboratory or animal studies rather than adequately powered human clinical trials.30,31,32,34
A randomized, double-blind, placebo-controlled phase II trial evaluated powdered Curcuma longa roots as an adjunct to standard treatment in children and adolescents with persistent asthma. Patients receiving Curcuma longa experienced less frequent nocturnal awakening, reduced use of short-acting β₂-agonists, and better asthma-control classification at selected assessment points. However, differences were not demonstrated for all evaluated clinical outcomes, and the findings require confirmation in larger trials.30
Experimental research on Zingiber officinale has demonstrated suppression of Th2-mediated allergic airway inflammation in ovalbumin-sensitized mice. Ginger extract and ginger-derived constituents were associated with reduced pulmonary eosinophilia, lower IL-4 and IL-5 concentrations, reduced allergen-specific IgE, decreased mucus production, and attenuation of oxidative stress. These results indicate preclinical potential but cannot be directly extrapolated to clinical treatment in humans.31
A hydroalcoholic stem extract of Tinospora cordifolia has also been studied in an ovalbumin-induced murine model of asthma. Treatment was associated with reductions in airway hyper-responsiveness, eosinophil counts, IgE, IL-4, tumour necrosis factor-α, oxidative stress, inflammatory mediators, and mucus hypersecretion. These findings support mechanistic and preclinical relevance but do not establish clinical efficacy or safety in patients with allergic asthma.32
A placebo-controlled, double-blind clinical study evaluated a proprietary herbal formulation containing Boswellia serrata gum resin and Aegle marmelos fruit extracts in patients with bronchial asthma. The intervention demonstrated improvement in selected respiratory symptoms and pulmonary outcomes compared with placebo. However, because the formulation contained multiple herbal components, the individual contribution of each plant could not be determined. Furthermore, additional large-scale randomized controlled trials are required before definitive conclusions regarding efficacy can be drawn.34
A recent systematic review and meta-analysis evaluating herbal medicines for asthma reported modest improvements in pulmonary function, particularly percentage-predicted forced expiratory volume in one second (FEV₁), when herbal interventions were used as adjuncts to conventional therapy. Nevertheless, substantial heterogeneity among study populations, herbal formulations, treatment durations, outcome measures, and methodological quality limits the generalizability of these findings. Consequently, current evidence should be regarded as encouraging but insufficient to recommend routine clinical use of any specific Ayurvedic herbal formulation for allergic asthma.35
Ayurvedic respiratory formulations commonly combine medicinal plants with complementary traditional and pharmacological actions, including expectoration, reduction of respiratory secretions, modulation of inflammation, improvement of digestion and metabolism, and immunomodulation. A limited number of clinical studies have evaluated herbal mixtures as adjunctive interventions in asthma.33,34,35
A placebo-controlled, double-blind clinical study evaluated a proprietary herbal composition containing extracts of Boswellia serrata gum resin and Aegle marmelos fruit in patients with asthma. The study reported improvements in selected respiratory symptoms and asthma-related parameters. However, because the intervention contained both plants, the observed outcomes cannot be attributed independently to either Boswellia serrata or Aegle marmelos. The proprietary nature of the preparation and the limited number of studies also restrict generalization of the findings.34
Systematic evaluation of herbal treatments for asthma has identified potentially favourable results in some clinical studies, but the overall evidence has been limited by heterogeneous interventions, small sample sizes, inconsistent diagnostic criteria, inadequate blinding, variation in treatment duration, and differences in pulmonary-function and symptom outcomes.33
A more recent systematic review and meta-analysis of randomized controlled trials reported a modest improvement in percentage-predicted forced expiratory volume in one second following herbal interventions used alongside conventional asthma therapy. Nevertheless, only a small number of trials were eligible for quantitative synthesis, and the included interventions were heterogeneous. These findings therefore do not validate any particular Ayurvedic plant, formulation, metered-dose inhaler, or nebulized herbal product.35
The majority of Ayurvedic medicinal plants proposed for allergic asthma have been investigated through in vitro assays, isolated-tissue studies, or animal models rather than adequately powered clinical trials. Experimental reductions in eosinophils, IgE, inflammatory cytokines, airway resistance, mucus production, oxidative stress, or histopathological inflammation may indicate pharmacological potential, but they do not guarantee clinical benefit in patients.31,32,33,35
Differences in botanical species, plant part, geographical source, cultivation conditions, harvesting period, purification procedures, extraction solvent, phytochemical composition, dose, route of administration, and storage conditions can substantially alter biological activity. Findings obtained using one standardized extract cannot automatically be applied to crude powders, decoctions, volatile oils, hydroalcoholic extracts, proprietary formulations, or inhalation products prepared from the same plant.29,33
Medicinal plants may also produce adverse effects or interact with corticosteroids, bronchodilators, anticoagulants, antihypertensive medicines, antidiabetic drugs, immunosuppressants, and other concurrent treatments. Ayurvedic interventions should therefore be described as potential adjunctive approaches requiring further validation and should not be presented as replacements for guideline-directed asthma-controller therapy.33,35
|
No. |
Ayurvedic name |
Botanical name |
Principal reported pharmacological activity |
Evidence level* |
Key limitation |
|
1 |
Vāsā |
Adhatoda vasica Nees |
Bronchodilator, expectorant, antitussive, anti-inflammatory |
Traditional + Preclinical |
Limited large RCTs |
|
2 |
Kaṇṭakārī |
Solanum xanthocarpum |
Reported bronchodilatory, anti-inflammatory and expectorant activities |
Preclinical |
Few clinical studies |
|
3 |
Pippalī |
Piper longum |
Immunomodulatory and bioavailability-modifying potential |
Preclinical |
Drug interaction potential |
|
4 |
Yaṣṭimadhu |
Glycyrrhiza glabra |
Anti-inflammatory, demulcent, antitussive |
Pharmacological + Limited Clinical |
Long-term glycyrrhizin toxicity |
|
5 |
Tulasī |
Ocimum tenuiflorum |
Immunomodulatory, antioxidant, anti-allergic |
Preclinical |
Limited human studies |
|
6 |
Haridrā |
Curcuma longa |
Anti-inflammatory, antioxidant, anti-remodelling |
Clinical + Preclinical |
Low oral bioavailability |
|
7 |
Śuṇṭhī |
Zingiber officinale |
Anti-inflammatory, anti-allergic, bronchodilator |
Preclinical |
Human evidence insufficient |
|
8 |
Śallakī |
Boswellia serrata |
5-Lipoxygenase inhibition, anti-inflammatory |
Limited formulation-specific clinical evidence |
Requires larger RCTs |
|
9 |
Antamūla |
Tylophora indica |
Anti-allergic, immunomodulatory |
Older Clinical Studies |
Gastrointestinal adverse effects |
|
10 |
Guḍūcī |
Tinospora cordifolia |
Immunomodulatory, antioxidant |
Preclinical |
Limited asthma trials |
|
11 |
Kalonji |
Nigella sativa |
Anti-inflammatory, antioxidant, bronchodilator |
Limited Clinical + Preclinical |
Dose standardization lacking |
|
12 |
Bilva |
Aegle marmelos |
Immunomodulatory, antioxidant |
Limited Clinical |
Mostly combination studies |
|
13 |
Puṣkaramūla |
Inula racemosa |
Bronchodilator, cardiopulmonary support |
Traditional + Preclinical |
Insufficient clinical evidence |
|
14 |
Bhāraṅgī |
Clerodendrum serratum |
Expectorant, anti-inflammatory |
Preclinical |
Limited human evidence |
|
15 |
Tālīsapatra |
Abies webbiana |
Expectorant, decongestant |
Traditional |
Standardization needed |
|
16 |
Elā |
Elettaria cardamomum |
Expectorant, antioxidant |
Traditional + Preclinical |
No asthma clinical trials |
|
17 |
Tvak |
Cinnamomum verum |
Anti-inflammatory, antioxidant |
Preclinical |
Coumarin-related safety concerns |
|
18 |
Lavaṅga |
Syzygium aromaticum |
Antioxidant, anti-inflammatory, antimicrobial |
Preclinical |
Essential oil may irritate airways |
|
19 |
Marica |
Piper nigrum |
Anti-inflammatory, bioavailability enhancer |
Preclinical |
Drug-metabolism interactions |
|
20 |
Rasona |
Allium sativum |
Antioxidant, anti-inflammatory |
General Clinical + Preclinical; limited asthma-specific evidence |
Bleeding risk with anticoagulants |
|
21 |
Nimba |
Azadirachta indica |
Immunomodulatory, anti-inflammatory |
Preclinical |
Limited safety data for asthma |
|
22 |
Aśvagandhā |
Withania somnifera |
Adaptogenic, immunomodulatory |
Preclinical |
Limited asthma-specific evidence |
|
23 |
Āmalakī |
Phyllanthus emblica |
Antioxidant, immunomodulatory |
Preclinical |
No direct asthma trials |
|
24 |
Śirīṣa |
Albizia lebbeck |
Anti-allergic, mast-cell stabilizing |
Preclinical |
Human evidence inadequate |
|
25 |
Agaru |
Aquilaria agallocha |
Aromatic expectorant |
Traditional |
Inhalation safety unknown |
|
26 |
Vibhītaka |
Terminalia bellirica |
Expectorant, antioxidant |
Traditional + Preclinical |
No clinical asthma studies |
|
27 |
Harītakī |
Terminalia chebula |
Anti-inflammatory, antioxidant |
Preclinical |
Clinical evidence lacking |
|
28 |
Bhūmyāmalakī |
Phyllanthus amarus |
Antioxidant, anti-inflammatory |
Preclinical |
No asthma-specific studies |
|
29 |
Apāmārga |
Achyranthes aspera |
Reported anti-inflammatory and respiratory activity |
Preclinical |
Human evidence limited |
|
30 |
Kulanjana |
Alpinia galanga |
Anti-inflammatory, antioxidant |
Preclinical |
Clinical efficacy unproven |
Evidence categories are descriptive and based on the nature of the available literature rather than formal certainty grading. “Preclinical” denotes in vitro or animal evidence; “limited clinical” denotes small, heterogeneous, or formulation-specific human studies; and “traditional” denotes use described in Ayurvedic literature without adequate modern clinical validation. Reported pharmacological activities should not be interpreted as established therapeutic efficacy in allergic asthma.
Pulmonary Safety and Translational Challenges of Herbal Inhalation Formulations:
Direct pulmonary administration of herbal extracts or volatile constituents presents safety considerations that differ substantially from those associated with oral Ayurvedic preparations. The respiratory epithelium is highly sensitive to particulate matter, concentrated volatile oils, residual solvents, microbial contaminants, endotoxins, allergens, oxidation products, and poorly characterized phytochemicals. A substance considered acceptable for oral administration cannot therefore be assumed to be safe for inhalation.40
Development of herbal metered-dose inhalers, dry-powder inhalers, or nebulized formulations requires evaluation of botanical identity, phytochemical composition, extract purity, residual solvents, microbial quality, elemental impurities, pesticide residues, aflatoxins, and degradation products. Formulation-specific parameters such as emitted-dose uniformity, aerodynamic particle-size distribution, fine-particle fraction, spray pattern, plume geometry, device compatibility, valve performance, and container-closure integrity must also be assessed.40,45
Preclinical pulmonary-safety evaluation should include acute and repeated-dose inhalation toxicity, respiratory irritation, bronchoconstriction potential, histopathological examination of lung tissue, inflammatory-cell analysis in bronchoalveolar lavage fluid, oxidative-stress markers, immunogenicity, and systemic exposure. Particular caution is required when volatile oils are incorporated because high concentrations of terpenes, phenolics, or oxidation products may irritate airway mucosa or provoke bronchospasm in susceptible individuals.
Accordingly, herbal inhalation formulations should remain investigational until their quality, aerosol performance, pulmonary tolerability, pharmacokinetics, efficacy, and long-term safety have been demonstrated through standardized preclinical and clinical studies.45
DISCUSSION:
Allergic asthma remains a major global health challenge despite substantial advances in understanding its immunopathogenesis and the availability of effective pharmacological therapies. Although inhaled corticosteroids, bronchodilators, leukotriene receptor antagonists, and biological agents have significantly improved disease control, many patients continue to experience recurrent exacerbations, medication-related adverse effects, reduced quality of life, and poor treatment adherence. These challenges have stimulated increasing interest in complementary therapeutic approaches capable of addressing multiple pathogenic mechanisms while supporting long-term disease management.36
The Ayurvedic description of Tamaka Shwasa demonstrates substantial clinical and functional similarities with allergic asthma. Both conditions are characterized by chronicity, recurrent respiratory symptoms, environmental trigger sensitivity, airway obstruction, nocturnal aggravation, and episodic exacerbations. Ayurveda explains disease progression through Doṣa imbalance, Āma formation, obstruction of the Prāṇavaha Srotas, and abnormal movement of Prāṇa Vāyu, whereas contemporary biomedicine attributes allergic asthma to chronic airway inflammation, eosinophilic infiltration, bronchial hyper-responsiveness, mucus hypersecretion, and structural airway remodelling. These concepts arise from distinct medical frameworks and should not be considered directly equivalent. Nevertheless, their clinical and functional similarities provide a useful hypothesis-generating framework for interdisciplinary research.37
Recent pharmacological investigations have provided preliminary scientific support for several Ayurvedic medicinal plants traditionally indicated for respiratory disorders. Experimental studies have reported anti-inflammatory, antioxidant, antitussive, expectorant, bronchodilatory, mucus-regulating, immunomodulatory, and antiallergic activities for selected herbal drugs. These multitarget effects may be relevant to airway inflammation, oxidative stress, mucus hypersecretion, bronchial smooth-muscle responses, and immune dysregulation. However, the majority of these findings originate from in vitro studies, animal experiments, or small clinical investigations and should not be interpreted as proof of therapeutic efficacy in patients with allergic asthma.38
The available clinical evidence remains insufficient for widespread implementation of Ayurvedic medicinal interventions in routine asthma management. Existing studies are limited by small sample sizes, methodological heterogeneity, inconsistent botanical and phytochemical standardisation, variation in formulation composition, short follow-up periods, inadequate blinding, and variability in diagnostic criteria and outcome measures. Furthermore, relatively few randomised controlled trials have evaluated authenticated and standardised Ayurvedic formulations using internationally accepted asthma-control measures, pulmonary-function parameters, inflammatory biomarkers, and long-term safety outcomes. Addressing these methodological weaknesses should remain a major priority for future clinical research.39
The development of standardised inhalation formulations derived from Ayurvedic medicinal plants represents a promising but technically demanding area of translational research. Modern aerosol-delivery systems allow therapeutic agents to be deposited directly in the respiratory tract, potentially increasing local drug concentration while reducing systemic exposure. Nevertheless, substances considered safe for oral use cannot automatically be assumed to be safe for pulmonary administration. Successful development of herbal metered-dose inhalers, dry-powder inhalers, or nebulised preparations requires comprehensive evaluation of botanical authentication, phytochemical composition, extract purity, formulation stability, emitted-dose uniformity, aerodynamic particle-size distribution, fine-particle fraction, device compatibility, pharmacokinetics, inhalation toxicology, respiratory irritation, immunogenicity, and long-term pulmonary safety.40
Overall, Ayurveda and contemporary respiratory medicine should be viewed as distinct yet potentially complementary healthcare system. Integration should not involve uncritical equivalence between classical Ayurvedic concepts and modern immunopathological mechanisms. Instead, it should be based on rigorous scientific validation, appropriate standardisation, transparent reporting, safety assessment, and clinically meaningful outcomes. Interdisciplinary collaboration among Ayurvedic scholars, pharmacologists, pharmaceutical scientists, pulmonologists, toxicologists, immunologists, and clinical researchers will be essential for translating traditional knowledge into safe, reproducible, and evidence-based interventions for allergic asthma.41
LIMITATIONS OF THE REVIEW:
This review has several limitations. First, it was conducted as a narrative review rather than a systematic review or meta-analysis; therefore, study selection and interpretation may have been influenced by the narrative synthesis process. Although multiple databases and classical Ayurvedic texts were examined, the absence of a formally registered systematic-review protocol may have increased the possibility of selection bias.
Second, the available evidence is highly heterogeneous with respect to medicinal-plant species, botanical identity, plant parts, geographical sources, extraction procedures, formulations, doses, routes of administration, comparators, treatment durations, and outcome measures. Such heterogeneity limits direct comparison among studies and prevents conclusions drawn from one extract or formulation from being generalised to all preparations containing the same medicinal plant.
Third, much of the evidence concerning Ayurvedic medicinal plants is derived from in vitro experiments, animal models, traditional use, or small clinical investigations with uncertain risk of bias. Experimental changes in eosinophils, IgE, cytokines, oxidative-stress markers, mucus production, or airway resistance do not necessarily translate into clinically meaningful improvement in asthma control, lung function, exacerbation frequency, or quality of life.
Fourth, classical Ayurvedic concepts and contemporary biomedical mechanisms originate from different epistemological and theoretical frameworks. Consequently, proposed comparisons involving Doṣa, Āma, Agni, Srotas, airway inflammation, immune dysregulation, and bronchial obstruction are interpretative and hypothesis-generating. They should not be regarded as evidence of direct biological equivalence.
Finally, language restriction, publication bias, incomplete reporting of negative findings, limited accessibility of some classical commentaries, and variability in the quality of both traditional and contemporary sources may have affected the comprehensiveness of the review. These limitations should be considered while interpreting the conclusions and translational implications of the available evidence.
FUTURE PERSPECTIVES:
The continuing global burden of allergic asthma and the limitations associated with long-term pharmacotherapy underscore the need for innovative, safe, and evidence-based therapeutic strategies. Ayurveda offers a holistic framework for disease prevention and long-term management through individualised assessment, avoidance of causative factors, dietary and lifestyle regulation, and medicinal interventions with potentially multitarget pharmacological actions. However, integration into contemporary respiratory care should proceed through scientific validation rather than reliance on traditional use alone.42
Future research should prioritise botanical authentication, voucher-specimen documentation, good agricultural and collection practices, phytochemical fingerprinting, identification and quantification of bioactive constituents, quality assurance, contaminant testing, and batch-to-batch consistency. Advanced approaches such as metabolomics, transcriptomics, proteomics, network pharmacology, systems biology, and artificial-intelligence-assisted data analysis may help clarify the complex molecular actions of multicomponent Ayurvedic formulations and identify biomarkers associated with therapeutic response.43
Well-designed multicentre randomised controlled trials are required to establish the clinical efficacy and safety of standardised Ayurvedic interventions in allergic asthma. Such studies should employ clearly defined asthma phenotypes and endotypes, adequate sample sizes, appropriate controls, allocation concealment, blinding wherever feasible, prospective registration, and sufficiently long follow-up periods. Outcome assessment should include validated asthma-control scores, spirometry, peak expiratory flow variability, exacerbation frequency, rescue-medication use, quality-of-life indices, blood eosinophil counts, serum IgE, fractional exhaled nitric oxide, and relevant inflammatory biomarkers. Clinical protocols should adhere to internationally recognised reporting guidelines to improve transparency, reproducibility, and comparability.44
Advances in pulmonary drug-delivery technology provide new opportunities for translating selected Ayurvedic phytopharmaceuticals into modern dosage forms. Development of metered-dose inhalers, dry-powder inhalers, soft-mist systems, and nebulised herbal preparations may permit targeted delivery to the respiratory tract. However, each formulation must undergo rigorous assessment of physicochemical stability, extract–excipient compatibility, aerosol performance, aerodynamic particle size, emitted-dose uniformity, fine-particle dose, container-closure integrity, device performance, inhalation toxicology, respiratory irritation, and long-term pulmonary tolerability before clinical use.45
Future integrative research should also examine herb–drug interactions, pharmacokinetic compatibility with inhaled corticosteroids and bronchodilators, pharmacovigilance, patient adherence, cost-effectiveness, and regulatory pathways for herbal inhalation products. Development of validated phytopharmaceuticals should involve collaboration among Ayurvedic physicians, botanists, pharmacognosists, pharmaceutical scientists, toxicologists, immunologists, pulmonologists, biostatisticians, and regulatory authorities. Such interdisciplinary efforts may expand therapeutic options while ensuring that Ayurvedic interventions are evaluated according to contemporary standards of quality, safety, and clinical efficacy.46
CONCLUSION:
Tamaka Shwasa, as described in Ayurveda, exhibits substantial clinical and conceptual similarities with allergic asthma, particularly with respect to recurrent respiratory obstruction, trigger sensitivity, mucus-associated breathing difficulty, nocturnal aggravation, and episodic exacerbations. Nevertheless, Ayurvedic concepts such as Doṣa, Āma, Agni, and Srotas do not possess established direct biomedical equivalents. The observed similarities should therefore be interpreted as comparative and hypothesis-generating rather than as proof of identical pathophysiological mechanisms.
Current experimental and limited clinical evidence suggests that selected Ayurvedic medicinal plants may possess anti-inflammatory, antioxidant, antitussive, expectorant, immunomodulatory, and antiallergic properties relevant to allergic airway disease. However, most available evidence originates from preclinical studies or small heterogeneous clinical investigations. These interventions should therefore be regarded as potential adjunctive approaches requiring further validation and not as replacements for established asthma-controller therapy.
Future progress in integrative respiratory medicine will depend on rigorous botanical and phytochemical standardisation, mechanistic investigations, pulmonary-safety assessment, multicentre randomised controlled trials, pharmacovigilance, and adherence to internationally accepted quality and regulatory standards. Meaningful collaboration between Ayurvedic scholars and contemporary biomedical researchers may facilitate the development of scientifically validated, safe, and patient-centred therapeutic strategies for allergic asthma.
1. Global Initiative for Asthma. Global strategy for asthma management and prevention: 2025 update. Fontana (WI): Global Initiative for Asthma; 2025.
2. World Health Organization. Asthma. Geneva: World Health Organization; 2024.
3. Jameson JL, Fauci AS, Kasper DL, Hauser SL, Longo DL, Loscalzo J, editors. Harrison’s Principles of Internal Medicine. 21st ed. New York: McGraw-Hill Education; 2022.
4. Agnivesha. Charaka Samhita, Chikitsa Sthana, Chapter 17. In: Acharya YT, editor. Charaka Samhita of Agnivesha with Ayurveda Dipika commentary of Chakrapanidatta. Reprint ed. Varanasi: Chaukhambha Surbharati Prakashan; 2020.
5. Kumar V, Abbas AK, Aster JC. Robbins and Cotran pathologic basis of disease. 11th ed. Philadelphia: Elsevier; 2021.
6. Vagbhata. Ashtanga Hridaya, Nidana Sthana, Chapter 4. In: Harisastri Paradakara V, editor. Reprint ed. Varanasi: Chaukhambha Orientalia; 2022.
7. Sushruta. Sushruta Samhita, Uttara Tantra, Chapter 51, with Nibandha Sangraha commentary of Dalhana. In: Acharya YT, editor. Reprint ed. Varanasi: Chaukhambha Surbharati Prakashan; 2020.
8. Monier-Williams M. A Sanskrit-English dictionary. Reprint ed. New Delhi: Motilal Banarsidass Publishers; 2005.
9. Sharma RK, Dash B. Charaka Samhita of Agnivesa. Vol. 5, Chikitsa Sthana. Varanasi: Chowkhamba Sanskrit Series Office; 2013.
10. Srikantha Murthy KR. Ashtanga Hridayam of Vagbhata. Vol. 2. Varanasi: Chaukhambha Krishnadas Academy; 2019.
11. Tripathi B. Madhava Nidana of Madhavakara. Varanasi: Chaukhambha Surbharati Prakashan; 2019.
12. Sharma PV. Dravyaguna Vijnana. Vol. 2. Varanasi: Chaukhambha Bharati Academy; 2020.
13. Mishra BS, Vaishya R. Bhavaprakasha of Bhavamishra. Varanasi: Chaukhambha Sanskrit Bhawan; 2020.
14. Papi A, Brightling C, Pedersen SE, Reddel HK. Asthma. Lancet. 2018;391(10122):783–800.
15. GBD 2021 Diseases and Injuries Collaborators. Global incidence, prevalence, years lived with disability, disability-adjusted life-years, and healthy life expectancy for 371 diseases and injuries in 204 countries and territories and 811 subnational locations, 1990–2021: a systematic analysis for the Global Burden of Disease Study 2021. Lancet. 2024;403(10440):2133–2161.
16. Pawankar R, Canonica GW, Holgate ST, Lockey RF, Blaiss MS, editors. WAO white book on allergy: update 2013. Milwaukee (WI): World Allergy Organization; 2013.
17. Lambrecht BN, Hammad H. The immunology of asthma. Nat Immunol. 2015;16(1):45–56.
18. Holgate ST. Pathogenesis of asthma. Clin Exp Allergy. 2008;38(6):872–897.
19. Global Initiative for Asthma. Difficult-to-treat and severe asthma in adolescent and adult patients: diagnosis and management. Fontana (WI): Global Initiative for Asthma; 2024.
20. Busse WW, Lemanske RF Jr. Asthma. N Engl J Med. 2001;344(5):350–362.
21. Barnes PJ. Asthma mechanisms. Medicine (Abingdon). 2023;51(4):231–238.
22. Holgate ST, Wenzel S, Postma DS, Weiss ST, Renz H, Sly PD. Asthma. Nat Rev Dis Primers. 2015; 1:15025.
23. Dharmage SC, Perret JL, Custovic A. Epidemiology of asthma in children and adults. Front Pediatr. 2019; 7:246.
24. Akdis CA, Arkwright PD, Brüggen MC, et al. Type 2 immunity in asthma and allergy. Nat Rev Immunol. 2020;20(2):114–130.
25. Masoli M, Fabian D, Holt S, Beasley R; Global Initiative for Asthma Program. The global burden of asthma: executive summary of the GINA Dissemination Committee report. Allergy. 2004;59(5):469–478.
26. Patwardhan B, Vaidya ADB, Chorghade M. Ayurveda and natural products drug discovery. Curr Sci. 2004;86(6):789–799.
27. Patwardhan B, Mutalik G, Tillu G. Integrative approaches for health: biomedical research, Ayurveda and yoga. London: Academic Press; 2015.
28. Dhuley JN. Antitussive effect of Adhatoda vasica extract on mechanical or chemical stimulation-induced coughing in animals. J Ethnopharmacol. 1999;67(3):361–365.
29. Claeson UP, Malmfors T, Wikman G, Bruhn JG. Adhatoda vasica: a critical review of ethnopharmacological and toxicological data. J Ethnopharmacol. 2000;72(1–2):1–20.
30. Manarin G, Anderson D, Silva JME, Coppede JS, Roxo-Junior P, Pereira AMS, et al. Curcuma longa L. ameliorates asthma control in children and adolescents: a randomized, double-blind, controlled trial. J Ethnopharmacol. 2019; 238: 111882.
31. Ahui MLB, Champy P, Ramadan A, Pham Van L, Araujo L, Brou André K, et al. Ginger prevents Th2-mediated immune responses in a mouse model of airway inflammation. Int Immunopharmacol. 2008;8(12):1626–1632.
32. Tiwari M, Dwivedi UN, Kakkar P. Tinospora cordifolia extract modulates COX-2, iNOS, ICAM-1, pro-inflammatory cytokines and redox status in a murine model of asthma. J Ethnopharmacol. 2014;153(2):326–337.
33. Singh BB, Khorsan R, Vinjamury SP, Der-Martirosian C, Kizhakkeveettil A, Anderson TM. Herbal treatments of asthma: a systematic review. J Asthma. 2007;44(9):685–698.
34. Yugandhar P, Rao KM, Sengupta K. A novel herbal composition containing extracts of Boswellia serrata gum resin and Aegle marmelos fruit alleviates symptoms of asthma in a placebo-controlled double-blind clinical study. Phytother Res. 2018;32(1):140–150.
35. Derakhshan A, Sadeghi M, Asnaashari AMH, Dehghani M, Salari R, Khadem-Rezaiyan M, et al. Efficacy of herbal medicines on lung function in asthma: a systematic review and meta-analysis of randomized controlled trials. J Pharmacopuncture. 2023; 26(2): 124–138.
36. Agustí A, Bafadhel M, Beasley R, Bel EH, Faner R, Gibson PG, et al. Precision medicine in airway diseases: moving to clinical practice. Eur Respir J. 2017; 50(4): 1701655.
37. Pavord ID, Beasley R, Agustí A, Anderson GP, Bel E, Brusselle G, et al. After asthma: redefining airways diseases. Lancet. 2018;391(10118):350–400.
38. Ekor M. The growing use of herbal medicines: issues relating to adverse reactions and challenges in monitoring safety. Front Pharmacol. 2014; 5:177.
39. Tilburt JC, Kaptchuk TJ. Herbal medicine research and global health: an ethical analysis. Bull World Health Organ. 2008; 86(8): 594–599.
40. Labiris NR, Dolovich MB. Pulmonary drug delivery. Part I: physiological factors affecting therapeutic effectiveness of aerosolized medications. Br J Clin Pharmacol. 2003; 56(6): 588–599.
41. Patwardhan B, Vaidya ADB. Chasing the dreams of integrative medicine. J Ayurveda Integr Med. 2010; 1(2): 91–99.
42. World Health Organization. Global traditional medicine strategy 2025–2034. Geneva: World Health Organization; 2025.
43. Patwardhan B, Chandran U. Network ethnopharmacology and systems Ayurveda: future directions for traditional medicine research. J Ayurveda Integr Med. 2015;6(2):73–74.
44. Chan AW, Tetzlaff JM, Gøtzsche PC, Altman DG, Mann H, Berlin JA, et al. SPIRIT 2013 statement: defining standard protocol items for clinical trials. Ann Intern Med. 2013; 158(3): 200–207.
45. Newman SP. Drug delivery to the lungs: challenges and opportunities. Ther Deliv. 2017; 8(8): 647–661.
46. Fasinu PS, Bouic PJD, Rosenkranz B. An overview of the evidence and mechanisms of herb–drug interactions. Front Pharmacol. 2012; 3: 69.
|
Received on 29.07.2026 Revised on 17.08.2026 Accepted on 01.09.2026 Published on 12.09.2026 Available online from September 19, 2026 Asian J. Research Chem.2026; 19(5):478-490. DOI: 10.52711/0974-4150.2026.00070 ©A and V Publications All Right Reserved
|
|
|
This work is licensed under a Creative Commons Attribution-Non Commercial-Share Alike 4.0 International License. Creative Commons License. |
|